(Q44221780)

1 December 2017

title

Suppression and transient induction of lymphokines in cancer patients after administration of polyethylene glycolated interleukin-2. (English)

1 reference

1 December 2017

Shih Y

1

1 reference

1 December 2017

Konrad MW

2

1 reference

1 December 2017

Warren MK

3

1 reference

1 December 2017

Childs A

4

1 reference

1 December 2017

Paradise C

5

1 reference

1 December 2017

Meyers FJ

6

1 reference

1 December 2017

Groves ES

7

1 reference

1 December 2017

language of work or name

English

0 references

publication date

1 March 1992

1 reference

European Journal of Immunology

1 December 2017

published in

1 reference

1 December 2017

volume

22

1 reference

1 December 2017

issue

3

1 reference

1 December 2017

page(s)

727-733

1 reference

Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients

1 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830220316

7 January 2021

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830220316

7 January 2021

Interleukin-2 initiates metabolic responses associated with critical illness in humans

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830220316

7 January 2021

Interleukin-2 administration causes reversible hemodynamic changes and left ventricular dysfunction similar to those seen in septic shock.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830220316

7 January 2021

Chemical modification of recombinant interleukin 2 by polyethylene glycol increases its potency in the murine Meth A sarcoma model

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830220316

7 January 2021

A phase I study including pharmacokinetics of polyethylene glycol conjugated interleukin-2.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830220316

7 January 2021

Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830220316

7 January 2021

Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830220316

7 January 2021

Interleukin-6 and its receptor during homeostasis, inflammation, and tumor growth

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830220316

7 January 2021

Acute Phase Reactant Proteins in the Clinical Management of Carcinoma of the Bladder

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830220316

7 January 2021

Reevaluation of C-reactive protein in cancer sera by radioimmunoassay and radial immunodiffusion. I. Diagnostic value and use in battery of conventional tumor markers

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830220316

7 January 2021

Comparison of serum amyloid A protein and C-reactive protein concentrations in cancer and non-malignant disease

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830220316

7 January 2021

Value of serum acute-phase reactant proteins and carcinoembryonic antigen in the preoperative staging of colorectal cancer a multivariate analysis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830220316

7 January 2021

https://api.crossref.org/works/10.1002%2FEJI.1830220316

1 reference

7 January 2021

Proliferating or interleukin 1-activated human vascular smooth muscle cells secrete copious interleukin 6.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830220316

7 January 2021

Cytokine regulation of interleukin 6 production by human endothelial cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830220316

7 January 2021

Response of resting human peripheral blood natural killer cells to interleukin 2.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830220316

7 January 2021

The p75 peptide is the receptor for interleukin 2 expressed on large granular lymphocytes and is responsible for the interleukin 2 activation of these cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830220316

7 January 2021

Interleukin 2 binding molecule distinct from the Tac protein: analysis of its role in formation of high-affinity receptors

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830220316

7 January 2021

Superinduction of the human gene encoding immune interferon.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830220316

7 January 2021

Induction, suppression and superinduction of lymphokine mRNA in T lymphocytes

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830220316

7 January 2021

Regulation of IL 2 expression in mitogen-activated murine T lymphocytes

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830220316

7 January 2021

EVIDENCE FOR TUMOUR NECROSIS FACTOR/CACHECTIN PRODUCTION IN CANCER

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830220316

7 January 2021

Induction of circulating tumor necrosis factor (TNF alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830220316

7 January 2021

Identifiers

DOI

10.1002/EJI.1830220316

1 reference

1 December 2017

1 reference